Cargando…

Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting

The study reports the response of first-line antiretroviral therapy (ART) by assessing CD4 and CD8 T-lymphocyte and viral load (VL) among Bangladeshi people living with HIV (PLHIV). This observational approach was conducted on 100 PLHIVs, grouped into therapy naive (n = 33), therapy initiators with...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashed Ul Islam, Shahria Mohammad, Jahan, Munira, Nessa, Afzalun, Tabassum, Shahina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900579/
https://www.ncbi.nlm.nih.gov/pubmed/31392926
http://dx.doi.org/10.1177/2325958219867329
_version_ 1783477376588447744
author Rashed Ul Islam, Shahria Mohammad
Jahan, Munira
Nessa, Afzalun
Tabassum, Shahina
author_facet Rashed Ul Islam, Shahria Mohammad
Jahan, Munira
Nessa, Afzalun
Tabassum, Shahina
author_sort Rashed Ul Islam, Shahria Mohammad
collection PubMed
description The study reports the response of first-line antiretroviral therapy (ART) by assessing CD4 and CD8 T-lymphocyte and viral load (VL) among Bangladeshi people living with HIV (PLHIV). This observational approach was conducted on 100 PLHIVs, grouped into therapy naive (n = 33), therapy initiators with CD4 T-cell count of <350 cells/µL (n = 33), and therapy receivers for >1 year prior to the study period (n = 34). Therapy initiators who continued the study (n = 20) were followed up after 12 and 24 weeks of therapy initiation. The CD4 and CD8 T-lymphocyte count estimation and (VL) were quantified. The mean CD4 T-lymphocyte count was significantly reduced among the therapy initiators in comparison to therapy naive and therapy receivers. Similar findings were observed for CD8 T-lymphocyte count among the study groups. The mean HIV-1 RNA VL among therapy initiators showed a significant decrease after 12 and 24 weeks, and 85% patients in this group obtained undetectable VL status indicating the good therapeutic outcome.
format Online
Article
Text
id pubmed-6900579
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-69005792019-12-12 Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting Rashed Ul Islam, Shahria Mohammad Jahan, Munira Nessa, Afzalun Tabassum, Shahina J Int Assoc Provid AIDS Care Original Article The study reports the response of first-line antiretroviral therapy (ART) by assessing CD4 and CD8 T-lymphocyte and viral load (VL) among Bangladeshi people living with HIV (PLHIV). This observational approach was conducted on 100 PLHIVs, grouped into therapy naive (n = 33), therapy initiators with CD4 T-cell count of <350 cells/µL (n = 33), and therapy receivers for >1 year prior to the study period (n = 34). Therapy initiators who continued the study (n = 20) were followed up after 12 and 24 weeks of therapy initiation. The CD4 and CD8 T-lymphocyte count estimation and (VL) were quantified. The mean CD4 T-lymphocyte count was significantly reduced among the therapy initiators in comparison to therapy naive and therapy receivers. Similar findings were observed for CD8 T-lymphocyte count among the study groups. The mean HIV-1 RNA VL among therapy initiators showed a significant decrease after 12 and 24 weeks, and 85% patients in this group obtained undetectable VL status indicating the good therapeutic outcome. SAGE Publications 2019-08-08 /pmc/articles/PMC6900579/ /pubmed/31392926 http://dx.doi.org/10.1177/2325958219867329 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Rashed Ul Islam, Shahria Mohammad
Jahan, Munira
Nessa, Afzalun
Tabassum, Shahina
Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting
title Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting
title_full Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting
title_fullStr Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting
title_full_unstemmed Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting
title_short Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting
title_sort response to first-line antiretroviral therapy among plhiv from a high-risk, low-prevalence setting
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900579/
https://www.ncbi.nlm.nih.gov/pubmed/31392926
http://dx.doi.org/10.1177/2325958219867329
work_keys_str_mv AT rashedulislamshahriamohammad responsetofirstlineantiretroviraltherapyamongplhivfromahighrisklowprevalencesetting
AT jahanmunira responsetofirstlineantiretroviraltherapyamongplhivfromahighrisklowprevalencesetting
AT nessaafzalun responsetofirstlineantiretroviraltherapyamongplhivfromahighrisklowprevalencesetting
AT tabassumshahina responsetofirstlineantiretroviraltherapyamongplhivfromahighrisklowprevalencesetting